News

The Launch and Scale Speedometer blog series. November 18, 2021 By Stephanie Stan [caption id="attachment_2946" align="aligncenter" width="300"] Source: WHO[/caption] Scaling Lifesaving Interventions Faster: A case study on the accelerated uptake of nOPV2, the first vaccine to receive WHO Emergency Use Listing  Widespread administration of oral polio vaccines (OPVs) has resulted in reduced incidence of polio and the eradication of wild poliovirus type 2 and type 31,2. Despite progress reducing the burden of polio globally, type 2 circulating vaccine-derived poliovirus (cVDPV2) has continued to spread, primarily through Africa and Asia1,3: in 2019, there were 366 cases of cVDPV2 globally and by 2020, this number had increased to 1,069 cases1,4,5. The novel oral polio vaccine type 2 (nOPV2)—a more genetically stable, next generation polio vaccine—was developed to prevent further spread and outbreaks of cVDPV2 throughout under-immunized populations, serving to save children from poliovirus-induced paralysis and death1. In…

The Launch and Scale Speedometer blog series. October 29, 2021 By Blen Biru Confirmed Vaccine Purchases Confirmed Donations (by recipient, includes pledges) High income countries 7 B 7 M Upper  middle income countries 2.6 B 75 M Lower middle income countries 2.6 B 84.7 M Low income countries 238 M 66 M COVAX 2.5 B 945 M WORLDWIDE TOTALS 15 B 1.2 B INSIGHTS Most high income and upper middle-income countries have fully vaccinated more than half of their population. Portugal ranks first having covered 85% of its population followed by UAE (83%) and Spain (78%). The US ranks 18th having 55% of its population fully vaccinated. In contrast, resource limited countries such as Nigeria, Ethiopia, and Tanzania have only vaccinated less than 5% of their population. In light of the new COVID-19 variants, countries such…